Trovagene announced the availability of its urine-based HPV-HR (high-risk) assay, a molecular human papillomavirus (HPV) test designed to identify the presence or absence of 15 known high-risk HPV strains using proprietary DNA sequences.
The HPV-HR DNA test is a non-invasive option that may improve the adoption and acceptance rate of HPV testing. The following HPV genotypes are tested: 16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 68, and 70. In a recent study, the Trovagene HPV-HR test was compared with the Qiagen hc2 High-Risk cervical cell DNA test. Using DNA sequencing as the gold standard, the false negative rate for the urine-based test was 5.6% compared with 16.8% for the hc2 assay. In addition, the false positive rate for the urine-based test was 5.0% compared with 17.6% for the hc2 assay.
The Trovagene HPV-HR test is available to patients through their healthcare providers.
For more information call (888) 391-7992 or visit www.trovagene.com/HPV.